US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bayer A.G.

10.55

-0.3900-3.56%

Post-market: 10.560.0100+0.09%16:00 EDT

Volume:2.10M

Turnover:22.12M

Market Cap:41.46B

PE:-16.67

High:10.61

Open:10.50

Low:10.41

Close:10.94

52wk High:14.85

52wk Low:6.99

Shares:3.93B

Float Shares:3.93B

Volume Ratio:1.46

T/O Rate:0.05%

Dividend:0.03

Dividend Rate:0.30%

EPS(TTM):-0.6327

EPS(LYR):-0.6723

ROE:-6.93%

ROA:3.64%

PB:1.23

PE(LYR):-15.69

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

Bayer Can Still Take Hit If Litigation Strategy Fails -- Market Talk

Bayer to present new data across oncology portfolio

Bayer announces Priority Review designation for Kerendia

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BAYRY"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BAYRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","market":"US","secType":"STK","nameCN":"Bayer A.G.","latestPrice":10.55,"timestamp":1780084800000,"preClose":10.94,"halted":0,"volume":2099760,"hourTrading":{"tag":"盘后","latestPrice":10.56,"preClose":10.55,"latestTime":"16:00 EDT","volume":55,"amount":580.8000000000001,"timestamp":1780084801447,"change":0.01,"changeRate":0.000948,"amplitude":0},"delay":15,"changeRate":-0.0356489945155392,"floatShares":3929259738,"shares":3929696328,"eps":-0.632721,"marketStatus":"Market Closed","change":-0.39,"latestTime":"05-29 16:00:01 EDT Delay","open":10.5,"high":10.61,"low":10.41,"amount":22119904.416700017,"amplitude":0.018282,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.632721,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"adrRate":0.25,"exchange":"OTCQX","adjPreClose":10.94,"volumeRatio":1.456444016967906},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","floatShares":3929259738,"roa":"3.64%","roe":"-6.93%","lyrEps":-0.672343,"volumeRatio":1.456444016967906,"shares":3929696328,"dividePrice":0.032074,"high":10.61,"amplitude":0.018282,"preClose":10.94,"low":10.41,"week52Low":6.99,"pbRate":"1.23","psRate":"0.79","week52High":14.85,"institutionHeld":0.0018,"latestPrice":10.55,"eps":-0.632721,"divideRate":0.00304,"volume":2099760,"delay":15,"ttmEps":-0.632721,"open":10.5,"prevYearClose":10.82,"prevWeekClose":11.11,"prevMonthClose":11.17,"prevQuarterClose":11.48,"fiveDayClose":11.28,"twentyDayClose":11.17,"sixtyDayClose":11.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BAYRY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-12","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"","actualEps":null},{"date":"2026-04-28","symbol":"BAYRY","amount":0.031526,"announcedDate":"2026-04-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-28","defaultRemindTime":1777383000000,"name":"Bayer A.G.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-11","payableDate":"2026-04-28","currency":"USD","dateTimestamp":1777348800000,"payDate":"2026-05-11"},{"market":"US","date":"2025-05-13","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"","actualEps":null},{"date":"2025-04-29","symbol":"BAYRY","amount":0.030365,"announcedDate":"2025-04-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-29","defaultRemindTime":1745933400000,"name":"Bayer A.G.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-04-29","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-05-12"},{"market":"US","date":"2024-11-12","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BAYRY\",market:\"US\",,,undefined,":[{"executeDate":"2019-04-29","recordDate":"2019-04-30","paymentDate":"2019-05-13","value":0.550569,"currency":"USD"},{"executeDate":"2020-04-29","recordDate":"2020-04-30","paymentDate":"2020-05-14","value":0.535933,"currency":"USD"},{"executeDate":"2021-04-28","recordDate":"2021-04-29","paymentDate":"2021-05-10","value":0.407111,"currency":"USD"},{"executeDate":"2022-05-02","recordDate":"2022-05-03","paymentDate":"2022-05-16","value":0.549114,"currency":"USD"},{"executeDate":"2023-05-02","recordDate":"2023-05-03","paymentDate":"2023-05-15","value":0.6318,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BAYRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":3,"updateTime":1763092800000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BAYRY\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2639986640","title":"Bayer's Key Pharma Products Face Competitive Risk -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2639986640","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639986640?lang=en_us&edition=fundamental","pubTime":"2026-05-29 16:15","pubTimestamp":1780042500,"startTime":"0","endTime":"0","summary":"0815 GMT - Bayer's pharmaceutical business has good momentum but faces risks over the medium term from potential competition to key products like its Kerendia kidney drug and asundexian for stroke prevention, Jefferies analysts say. The German group's pharma division should deliver annual sales growth of 2% over the 2025-2030 period, compared with the average growth rate of 5% among peers, according to Jefferies. Asundexian's potential market is a lot smaller after a trial for a type of heart arrhythmia known as atrial fibrillation failed and Bristol Myers Squibb's rival treatment milvexian could have an edge, they add. For Bayer's Kerendia, momentum is good for now, but the threat of competition looms on the horizon with AstraZeneca and Mineralys Therapeutics developing a new class of drugs, Jefferies says. Bayer shares fall 1.3%. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY","IE00BJT1NW94.SGD","LU0289739699.SGD","IE00B2B36J28.USD","LU1718418525.SGD","IE0009355771.USD","AZNH","LU0225284248.USD","IE00BJJMRZ35.SGD","LU1670710661.SGD","LU1829250122.USD","LU0058720904.USD","LU1074936037.SGD","LU2237443622.USD","LU0061475181.USD","LU0225771236.USD","LU1430594728.SGD","BK4007","LU2237443895.HKD","LU1989771016.USD","AZN","LU0306806265.USD","LU2242646821.SGD","LU0321505868.SGD","BK4139","LU2462157665.USD","LU1585245621.USD","BK4532","LU0456855351.SGD","BK4568","LU1670710588.SGD","LU1291159041.SGD","LU2456880835.USD","BAYRY","LU1323610961.USD","MLYS","IE0002141913.USD","LU0889565916.HKD","LU2125154935.USD","LU2125154778.USD","LU2237443382.USD","LU0882574055.USD","LU1670711123.USD","LU1868837300.USD","LU2360032135.SGD","LU2242652126.USD","LU1868836757.USD","IE00BFXG1179.USD","LU0432979614.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639647100","title":"Bayer Can Still Take Hit If Litigation Strategy Fails -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2639647100","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639647100?lang=en_us&edition=fundamental","pubTime":"2026-05-29 15:42","pubTimestamp":1780040520,"startTime":"0","endTime":"0","summary":"0741 GMT - Bayer's U.S. legal battles remain the main source of uncertainty looming over its shares, which could take a hit if the company's litigation strategy doesn't go to plan, Jefferies analysts say in a research note. The German agricultural-and-pharmaceutical conglomerate has captured a substantial majority of its litigation risk with an 11.8 billion-euro provision structure, according to Jefferies. That said, an adverse litigation outcome could prompt generalist investors to pivot out of Bayer, the analysts say. \"Bayer may become significantly more investable, but this is not a given.\" Jefferies raises its target price on Bayer stock to 40 euros from 25 euros. Shares fall 0.8% to 37.55 euros. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637914335","title":"Bayer to present new data across oncology portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2637914335","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637914335?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:20","pubTimestamp":1779366045,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced that new data from studies across their oncology portfolio will be presented at the upcoming 2026 American Society of Clini...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-to-present-new-data-across-oncology-portfolio-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-to-present-new-data-across-oncology-portfolio-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BAYRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637075381","title":"Bayer announces Priority Review designation for Kerendia","url":"https://stock-news.laohu8.com/highlight/detail?id=2637075381","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637075381?lang=en_us&edition=fundamental","pubTime":"2026-05-21 17:45","pubTimestamp":1779356710,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced that the FDA accepted its supplemental new drug application and granted Priority Review designation for Kerendia, which is ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-announces-priority-review-designation-for-kerendia-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-announces-priority-review-designation-for-kerendia-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","BK4585","BAYRY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":18,"pageCount":1,"totalSize":71,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BAYRY\",params:#limit:6,delay:false,,,undefined,":[]}}